Short answer
STANDARD BIOTOOLS INC. (LAB) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $20M (up 1590.8% year over year) with net income of −$27M.
Q2 2026 key financials · XBRL
- Revenue
- $20M
- +1590.8% YoY · −4.9% QoQ
- Net income
- −$27M
- +20.0% YoY · −121.1% QoQ
- Operating margin
- -126.3%
- Gross margin
- 52.4%
- EPS (diluted)
- −$0.07
- +22.2% YoY · −121.2% QoQ
Source: XBRL data from the STANDARD BIOTOOLS INC. (LAB) Q2 2026 10-Q on SEC EDGAR. USD.
STANDARD BIOTOOLS INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $20.1M, down 8% YoY from $21.8M, driven by consumables down 10% to $9.4M
- Gross margin 52.4% vs 48.8% YoY; net loss $26.8M vs $33.5M
- Best performer consumables at $9.4M; instruments declined 2% to $5.1M
- Cash, equivalents and investments $544.0M vs $213.3M at December 31, 2025
- Six-month operating cash use $56.9M vs $51.0M; merger expected to close second half of 2026
Risk Factors
- Nasdaq compliance risk: $1.00 bid-price deficiency recurred July 22, 2026, with compliance deadline January 19, 2027
- Merger execution risk: Closing remains subject to stockholder, Nasdaq listing, Form S-4 effectiveness, and other conditions
- Merger termination exposure: $16.1 million cash fee plus up to $5 million expense reimbursement
- Strategic transition risk: Combined company expected to shift from instruments to clinical-stage biopharmaceuticals
- Ownership dilution risk: Treeline holders expected to own 84% versus current stockholders’ 16% post-merger
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other STANDARD BIOTOOLS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.